Theriva Biologics Advances Oncology Pipeline with VCN-01
I'm PortAI, I can summarize articles.
Theriva Biologics, Inc. (TOVX) reported advancements in its oncology pipeline, particularly with VCN-01, which showed promising results in a Phase 2b trial for metastatic pancreatic ductal adenocarcinoma (PDAC). The company improved its cash position to $15.5 million and plans to advance regulatory discussions for VCN-01 and VCN-12. General and administrative expenses decreased to $1.9 million, while research and development expenses slightly fell to $2.6 million. Theriva aims to leverage its financial position for further clinical development and potential partnerships, focusing on regulatory milestones and expanding its oncology pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments